4 Approvals Coming (Mcap 31 M) Low Float 4 M

[BiotechMaster]

This Undiscovered low float Play awaiting 4 approvals .

A new Partnership coming any day now .This is a real Goldmine.

I think $15++ is very realistic for 2011 .GL


Intellipharmaceutics (IPCI)

Market Cap: 31 M
Price: $2.85

Shares Out: 10.9 M ...( 6 M Shares held by CEO)


Monster Pipeline
http://www.intellipharmaceutics.com/pipeline.cfm


Intellipharmaceutics Submits 4th ANDA in 12 Months
Intellipharmaceutics Submits 4th ANDA in 12 Months - ProActive Newsroom - pitchengine.com


Great Article ..A must READ
No News is Good News for IntelliPharmaCeutics International Inc. (IPCI) - International Business Times


Another great Article
Intellipharmaceutics CEO moulded at Biovail U - Bio Tuesday - Seeking Alpha


Interview with CEO
NASDAQ CEO Signature Series Interview – Dr Isa Odidi CEO Intellipharmaceutics International Inc | MBAs Portal



Intellipharmaceutics (IPCI) Takes Step Forward with Protonix® Generic | Stock Market News & Stocks to Watch from StraightStocks

Intellipharmaceutics (IPCI) Takes Step Forward with Protonix® Generic

Posted on Friday, December 24th, 2010 | In Biotech, Current Market News


No Response from Wyeth is a Positive Sign

12.22.2010– Intellipharmaceutics International, Inc. reported this morning that it has not received any contention of patent infringement, as provided for under the Hatch-Waxman Act, from Wyeth Pharmaceuticals pertaining to Intellipharmaceutics’ Abbreviated New Drug Application (ANDA) for a generic version of Protonix® (delayed-release pantoprazole sodium) tablets. Per ANDA protocol, as the brand owner of Protonix®, Wyeth, a wholly-owned subsidiary of Pfizer, Inc. (NYSE:PFE), was informed by Intellipharmaceutics that it had submitted paragraph IV certifications of invalidity and non-infringement for the patents that cover Protonix®.

The Hatch-Waxman Act allots 45 days for Wyeth to make a claim of patent infringement, which, to the best of Intellipharmaceutics’ knowledge, Wyeth did not. If a contention of patent infringement would have been filed, there is an automatic 30-month stay of FDA approval, which now will not be effected and opens the door for Intellipharmaceutics to move forward with marketing its generic drug pending FDA approval. The ANDA was accepted by the U.S. Food and Drug Administration in October of 2010.

This is a major step in the right direction for Intellipharmaceutics and its tiny market cap of under $30 million, as Protonix® sales approached $2 billion in 2009 for Wyeth. An FDA approval is never guaranteed, but this news puts Intellipharmaceutics in a prime position if the generic is granted in 2011. Presently, Protonix is prescribed as a therapy to limit gastric acid secretion as well as for the short-term treatment of conditions such as stomach ulcers associated with gastroesophageal reflux disease as well as the long term treatment of pathological hypersecretory conditions including Zollinger-Ellison syndrome, a rare disorder characterized by one or more tumors in the pancreas, duodenum, or both, which cause the stomach to make too much acid.

The Toronto, Canada-based biotech, which trades on both the U.S. Stock Exchange (NASDAQ:IPCI) and Toronto Stock Exchange (TSX:I), boasts a wealth of potential in its portfolio and has more than a handful of ANDA’s currently under review by the U.S.F.D.A. Along with the generic for Protonix®, Intellipharmaceutics has filed ANDA’s for generic versions of Focalin XR® (marketed by Novartis) and Effexor XR® (marketed by Pfizer) which, combined, total nearly $3 billion in sales for Novartis and Pfizer. Also, coming down the pipeline from Intellipharmaceutics are numerous drugs in various stages of development that are based on the Company’s patented Hypermatrix™ technology, which is a unique and validated multidimensional controlled-release drug delivery platform that can be applied to the efficient development of a wide range of existing and new pharmaceuticals. Intellipharmaceutics believes that this technology can improve therapies in many areas including neurology, cardiovascular, GIT, pain and infection.

With a small number of outstanding shares, a chart that is establishing an upward channel, a pipeline of potential candidates, several pending ANDA’s and a small market cap, Intellipharmaceutics International, Inc. may soon be hitting the radar of biotech traders looking for a company with large upside potential in 2011.

[gmarini]

Intellipharmaceutics International Inc. (Nasdaq: IPCI) announced that the Nasdaq Stock Market has granted the Company an extension of the deadline to regain compliance with Nasdaq Listing Rule 5550(b).
Listing Rule 5550(b) requires that companies listed on the Nasdaq Capital Market maintain a minimum of $2,500,000 in shareholders' equity, $35,000,000 in market value of listed securities or $500,000 in net income from continuing operations.
Under the terms of the extension, the Company must complete certain transactions on or before January 31, 2011 and demonstrate compliance with Listing Rule 5550(b) prior to March 1, 2011.
News Provided by Acquire Media Corporation

[giasone]

Good call Master... as usual !

Thanks once again !

IPCI +37%

[BiotechMaster]

Thanks.You are welcome gas .



IPCI is on the move ..Its still very very cheap .gl
Intellipharmaceutics (IPCI) Takes Step Forward with Protonix® Generic | Stock Market News & Stocks to Watch from StraightStocks

[gmarini]

Yeah.... I missed the bus ... I'm not sure if I should jump in right now

[BiotechMaster]

Up in pre market again . A close above current 52W high will be major positive

[gmarini]

It's a roller-coaster ..... up and down .... it's below the 150 SMA

[blconnell]

Mr. BioTechMaster,

How fast do you see this going to $15? This sounds like a good buy and hold candidate and wanted to test the waters before jumping in.

Your input is greatly appreciated.